AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch
ByAinvest
Tuesday, Sep 2, 2025 7:06 am ET1min read
Zenas BioPharma and Royalty Pharma have entered into a funding agreement for up to $300 million. The initial $75 million will fund the potential US commercial launch of obexelimab for IgG4-Related Disease. Additional $150 million is associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for IgG4-Related Disease treatment. This agreement will support obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet